We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 13, 2020

Improved Response and Survival With Cabozantinib in Patients With Advanced RCC Regardless of Age

European Journal of Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Outcomes Based on Age in the Phase III METEOR Trial of Cabozantinib Versus Everolimus in Patients With Advanced Renal Cell Carcinoma
Eur. J. Cancer 2020 Feb 01;126(xx)1-10, F Donskov, RJ Motzer, E Voog, E Hovey, C Grüllich, LM Nott, K Cuff, T Gil, NV Jensen, C Chevreau, S Negrier, R Depenbusch, L Bergmann, I Cornelio, A Champsaur, B Escudier, S Pal, T Powles, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading